GlassScriptPhysician profile
Thomas J Hurm
NPI 1730121773
$19,827.45
in general payments reported to CMS, 2019-2025
63 companies · $2,577 in 2025
The $2,577 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,950 · 2020: $2,029 · 2021: $2,563 · 2022: $3,558 · 2023: $3,097 · 2024: $3,054 · 2025: $2,577.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,721 · Education: $6.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,721.43 |
| Education | $6.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,297.89 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $2,745.80 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $1,495.91 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $1,431.62 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $1,338.14 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $885.88 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Amgen INC. | $840.97 | 2019-2025 | Repatha, Otezla, Otezla |
| Pfizer INC. | $796.31 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $554.18 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $542.37 | 2019-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $495.99 | 2019-2024 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $468.86 | 2019-2025 | Verquvo, Gardasil 9, Vaxneuvance |
| Takeda Pharmaceuticals U.S.A., INC. | $462.14 | 2019-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $347.12 | 2020-2023 | Austedo |
| Biohaven Pharmaceuticals, INC. | $317.64 | 2021 |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Hurm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.